ZA200708600B - Novel liposome compositions - Google Patents

Novel liposome compositions

Info

Publication number
ZA200708600B
ZA200708600B ZA200708600A ZA200708600A ZA200708600B ZA 200708600 B ZA200708600 B ZA 200708600B ZA 200708600 A ZA200708600 A ZA 200708600A ZA 200708600 A ZA200708600 A ZA 200708600A ZA 200708600 B ZA200708600 B ZA 200708600B
Authority
ZA
South Africa
Prior art keywords
liposome compositions
novel liposome
novel
compositions
liposome
Prior art date
Application number
ZA200708600A
Other languages
English (en)
Inventor
Okada Kazuski
Ibuki Tadayaki
Kim Donghyun
Fujisawa Tadashi
Original Assignee
Mebiopharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mebiopharm Co Ltd filed Critical Mebiopharm Co Ltd
Publication of ZA200708600B publication Critical patent/ZA200708600B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200708600A 2005-03-10 2006-03-08 Novel liposome compositions ZA200708600B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005067469A JP2006248978A (ja) 2005-03-10 2005-03-10 新規なリポソーム製剤

Publications (1)

Publication Number Publication Date
ZA200708600B true ZA200708600B (en) 2009-01-28

Family

ID=36992280

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708600A ZA200708600B (en) 2005-03-10 2006-03-08 Novel liposome compositions

Country Status (22)

Country Link
US (3) US7829113B2 (US07829113-20101109-C00019.png)
EP (1) EP1863448B1 (US07829113-20101109-C00019.png)
JP (2) JP2006248978A (US07829113-20101109-C00019.png)
KR (1) KR101352490B1 (US07829113-20101109-C00019.png)
CN (1) CN101170995B (US07829113-20101109-C00019.png)
AU (1) AU2006223329B2 (US07829113-20101109-C00019.png)
BR (1) BRPI0608297A2 (US07829113-20101109-C00019.png)
CA (1) CA2600446A1 (US07829113-20101109-C00019.png)
CY (1) CY1116075T1 (US07829113-20101109-C00019.png)
DK (1) DK1863448T3 (US07829113-20101109-C00019.png)
ES (1) ES2529453T3 (US07829113-20101109-C00019.png)
HK (1) HK1111625A1 (US07829113-20101109-C00019.png)
HU (1) HUE024290T2 (US07829113-20101109-C00019.png)
MX (1) MX2007010996A (US07829113-20101109-C00019.png)
NO (1) NO20075136L (US07829113-20101109-C00019.png)
NZ (1) NZ561569A (US07829113-20101109-C00019.png)
PL (1) PL1863448T3 (US07829113-20101109-C00019.png)
PT (1) PT1863448E (US07829113-20101109-C00019.png)
RU (1) RU2454229C2 (US07829113-20101109-C00019.png)
SI (1) SI1863448T1 (US07829113-20101109-C00019.png)
WO (1) WO2006099169A2 (US07829113-20101109-C00019.png)
ZA (1) ZA200708600B (US07829113-20101109-C00019.png)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101462825B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术(石家庄)有限公司 一种脂质体药物及其制备方法
US20120003294A1 (en) * 2007-08-17 2012-01-05 Celator Pharmaceuticals, Inc. Fixed ratio camptothecens/platinum agents
JP5872160B2 (ja) * 2007-09-10 2016-03-01 ボストン バイオメディカル, インコーポレイテッド 癌治療のための新規の組成物および方法
TWI468188B (zh) * 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
AU2010270722B2 (en) * 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
EP2480208A1 (en) * 2009-09-23 2012-08-01 Indu Javeri Methods for the preparation of liposomes
US10143652B2 (en) * 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
CN103025159A (zh) 2010-03-19 2013-04-03 波士顿生物医学公司 靶向癌症干细胞的新方法
WO2011128896A1 (en) * 2010-04-12 2011-10-20 Ramot At Tel-Aviv University Ltd. Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders
AU2011325966B2 (en) 2010-11-12 2016-09-29 Oncour Pharma, Inc. Modified immune-modulating particles
WO2012153616A1 (ja) * 2011-05-10 2012-11-15 国立大学法人北海道大学 標的細胞移行能を有する脂質膜構造体、その製造方法および標的細胞において効果を示す物質のスクリーニング方法
WO2013011598A1 (ja) * 2011-07-15 2013-01-24 コニカミノルタホールディングス株式会社 溶解助剤を利用したリポソーム含有製剤およびその製造方法
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
JP2015509085A (ja) * 2012-01-01 2015-03-26 キュービーアイ エンタープライゼズ リミテッドQbi Enterprises Ltd. 治療剤および診断剤の選択的送達のためのendo180を標的とする粒子
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
CA3211102A1 (en) * 2012-06-21 2013-12-27 Northwestern University Peptide conjugated particles
WO2014025042A1 (ja) 2012-08-10 2014-02-13 大鵬薬品工業株式会社 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
AU2013360302C1 (en) 2012-12-12 2019-01-24 Temple University - Of The Commonwealth System Of Higher Education Compositions and methods for treatment of cancer
CN103083239B (zh) * 2012-12-26 2015-11-25 中国人民解放军第四军医大学 一种蟾毒灵脂质体及其制备方法和应用
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
BR112015022476A2 (pt) * 2013-03-13 2017-07-18 Mallinckrodt Llc composições de oxaliplatina de lipossoma para terapia de câncer
MX2015012199A (es) * 2013-03-13 2015-11-30 Mallinckrodt Llc Composiciones de cisplatino liposomal para la terapia contra el cancer.
AU2014243758B2 (en) 2013-03-13 2019-02-07 Oncour Pharma, Inc. Immune-modifying particles for the treatment of inflammation
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル, インコーポレイテッド がんの処置に使用するための2−アセチルナフト[2,3−b]フラン−4,9−ジオン
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
AU2014306603B2 (en) 2013-08-13 2020-03-12 Northwestern University Peptide conjugated particles
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
WO2016070129A1 (en) 2014-10-30 2016-05-06 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
LT3066201T (lt) 2013-11-07 2018-08-10 Editas Medicine, Inc. Su crispr susiję būdai ir kompozicijos su valdančiomis grnr
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US20170007700A1 (en) * 2014-02-21 2017-01-12 The Curators Of The University Of Missouri Compositions and methods for boron neutron capture therapy
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
EP3315487B1 (en) 2015-06-24 2020-10-28 Nippon Kayaku Kabushiki Kaisha Novel platinum (iv) complex
CN108348480A (zh) 2015-08-20 2018-07-31 益普生生物制药有限公司 使用脂质体伊立替康和parp抑制剂用于癌症治疗的组合疗法
EP3791876A1 (en) 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
WO2017047497A1 (ja) 2015-09-14 2017-03-23 日本化薬株式会社 6配位白金錯体の高分子結合体
CN114073678A (zh) 2015-10-16 2022-02-22 易普森生物制药有限公司 稳定喜树碱药物组合物
WO2017070633A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Evolved cas9 proteins for gene editing
US20180318216A1 (en) * 2015-11-20 2018-11-08 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
CN108473676B (zh) 2015-12-22 2021-04-27 日本化药株式会社 亚砜衍生物配位铂(ii)络合物的高分子偶联物
CN110590855B (zh) 2016-01-25 2023-05-12 沈阳药科大学 铂类配合物的制备方法及其含有该铂类配合物的脂质体与制备方法
CN117757795A (zh) * 2016-03-07 2024-03-26 美国政府(由卫生和人类服务部的部长所代表) 微小rna及其使用方法
JP6606600B2 (ja) * 2016-04-15 2019-11-13 富士フイルム株式会社 マイクロニードルアレイ
CN109562067A (zh) * 2016-08-02 2019-04-02 库里尔克思股份有限公司 制备脂质体的方法
SG11201900907YA (en) 2016-08-03 2019-02-27 Harvard College Adenosine nucleobase editors and uses thereof
EP3497214B1 (en) 2016-08-09 2023-06-28 President and Fellows of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
CN109789212A (zh) 2016-08-12 2019-05-21 L.E.A.F.控股集团公司 聚谷氨酸化抗叶酸剂及其用途
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CA3039928A1 (en) 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
CA3040395A1 (en) 2016-11-02 2018-05-11 Ipsen Biopharm Ltd. Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
WO2018087720A1 (en) 2016-11-14 2018-05-17 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
EP3634385A4 (en) * 2017-05-12 2021-03-03 Curinanorx, LLC LIPOSOME PREPARATION PROCESSES INCLUDING MEDICINAL PRODUCTS
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. USES OF BASIC EDITORS ADENOSINE
CA3090387A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
CA3090494A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
US11771700B2 (en) 2018-02-14 2023-10-03 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
CN108524450A (zh) * 2018-04-16 2018-09-14 温州医科大学 基于磁性热敏阳离子脂质体的奥沙利铂和mdc1-as共传递药物载体的制备及应用
WO2020069373A1 (en) 2018-09-28 2020-04-02 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
KR20210093232A (ko) 2018-10-09 2021-07-27 더 유니버시티 오브 브리티시 콜롬비아 유기용매와 세제가 없는 형질감염 적격 소포를 포함하는 조성물과 시스템 및 관련 방법
AU2020242032A1 (en) 2019-03-19 2021-10-07 Massachusetts Institute Of Technology Methods and compositions for editing nucleotide sequences
CN111721841B (zh) * 2019-03-19 2022-07-12 海南长安国际制药有限公司 与洛铂有关物质的检测
CN110292563B (zh) * 2019-06-12 2021-07-16 兰州大学 基于叶酸热敏脂质体的阴离子载体诱导癌细胞凋亡的方法
AU2021246530A1 (en) 2020-04-02 2022-11-03 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides
KR20230019843A (ko) 2020-05-08 2023-02-09 더 브로드 인스티튜트, 인코퍼레이티드 표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물
CN112129871B (zh) * 2020-09-04 2021-06-15 斯微(上海)生物科技有限公司 复合磷脂脂质体中dope和m5两种磷脂含量的检测方法
CN112870164B (zh) * 2021-01-25 2021-12-17 山东大学 一种双靶向载药脂质体及其制备方法和应用
WO2023196851A1 (en) 2022-04-06 2023-10-12 President And Fellows Of Harvard College Reversing aging of the central nervous system

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GR75598B (US07829113-20101109-C00019.png) 1980-04-29 1984-08-01 Sanofi Sa
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4565696A (en) * 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
US4925661A (en) * 1984-04-19 1990-05-15 Leaf Huang Target-specific cytotoxic liposomes
US4789633A (en) 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4762915A (en) * 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
EP0211042A1 (en) * 1985-01-18 1987-02-25 Cooper-Lipotech, Inc. Liposome composition and method
US5026651A (en) * 1985-04-25 1991-06-25 Board Of Regents, The University Of Texas System Methods and compositions for the production of human transferrin
PH26160A (en) * 1985-08-19 1992-03-18 Univ Texas Pharmaceutical compositions consisting of acylated phospholipids
US4983397A (en) * 1985-08-19 1991-01-08 Board Of Regents, University Of Texas System Pharmaceutical compositions consisting of acylated phospholipids
US5384127A (en) * 1985-10-18 1995-01-24 Board Of Regents, The University Of Texas System Stable liposomal formulations of lipophilic platinum compounds
JPH0714865B2 (ja) * 1986-10-28 1995-02-22 武田薬品工業株式会社 リポソ−ム製剤およびその製造法
US5049390A (en) * 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
FR2631826B1 (fr) * 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
EP1327454A3 (en) * 1989-08-02 2003-12-03 Mitra Medical Technology AB Method of treatment with medical agents
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2093665A1 (en) * 1990-10-09 1992-04-10 Sean M. Sullivan Phospholipid analogue vesicle
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US6509032B1 (en) 1991-08-28 2003-01-21 Mcmaster University Cationic amphiphiles
US5292524A (en) * 1991-09-06 1994-03-08 California Institute Of Technology Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus
JPH0776230B2 (ja) * 1992-01-13 1995-08-16 田中貴金属工業株式会社 白金化合物の製造方法
JP2673331B2 (ja) * 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート(トランス―1―1,2―シクロヘキサンジアミン)白金(▲ii▼)
JPH06287021A (ja) * 1992-04-22 1994-10-11 Tanaka Kikinzoku Kogyo Kk 光学活性な白金錯化合物の光学的分割方法
US20030190638A1 (en) 1992-05-13 2003-10-09 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
US5962316A (en) * 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US20030100489A1 (en) * 1992-10-16 2003-05-29 Beach David H. Cell-cycle regulatory proteins, and uses related thereto
WO1994026254A1 (en) 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス.アー. 光学的に高純度なシス−オキザラート(トランス−l−1,2−シクロヘキサンジアミン)白金(II)錯体の製造方法
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
CA2150939C (en) * 1993-10-06 2001-05-01 David Collins Stable protein: phospholipid compositions and methods
AU1552995A (en) * 1993-12-17 1995-07-03 Spinal Cord Society Method for inducing dna synthesis in neurons
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
JP3590983B2 (ja) * 1994-03-04 2004-11-17 日本油脂株式会社 リン脂質誘導体
DE69527194T2 (de) 1994-03-28 2003-02-06 Nycomed Imaging As Liposomen enthaltend ein röntgen- oder ultraschallkontrastmittel
CA2192836A1 (en) 1994-07-29 1996-02-15 Anthony R. Haight Process for the preparation of a substituted 2.5-diamino-3-hydroxyhexane
BR9508554A (pt) 1994-08-08 1997-11-25 Debiopharm Sa Preparação farmaceuticamente estável de oxaliplatina
DK0785773T3 (da) * 1994-10-14 2001-01-29 Liposome Co Inc Etherlipidliposomer og deres terapeutiske anvendelse
EP0715854B1 (en) 1994-11-11 2003-09-10 Debiopharm S.A. Carcinostatic compositions containing cis-oxaliplatinum and one or more other compatible carcinostatic substances
US5786214A (en) * 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
TW319763B (US07829113-20101109-C00019.png) 1995-02-01 1997-11-11 Epix Medical Inc
US5780052A (en) * 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
US5834012A (en) * 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
US20020022264A1 (en) 1995-05-26 2002-02-21 Sullivan Sean M. Delivery vehicles comprising stable lipid/nucleic acid complexes
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
JPH09278785A (ja) 1996-04-10 1997-10-28 Tanaka Kikinzoku Kogyo Kk 白金化合物の製造方法
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US6428977B1 (en) 1995-12-20 2002-08-06 Curis, Inc. Signalin family of TGFβ signal transduction proteins, and uses related thereto
JP3735921B2 (ja) * 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 GPIb・脂質複合体およびその用途
WO1997028817A1 (en) * 1996-02-09 1997-08-14 Cheng Pi Wan Receptor ligand-facilitated delivery of biologically active molecules
JP3862758B2 (ja) 1996-03-11 2006-12-27 喜徳 喜谷 二核白金錯体、その調製方法及びその錯体を含有する医薬組成物
AU2549297A (en) * 1996-03-28 1997-10-17 Board Of Trustees Of The University Of Illinois, The Materials and methods for making improved echogenic liposome compositions
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス.アー. 白金化合物の製造方法
JP3919227B2 (ja) * 1996-05-02 2007-05-23 テルモ株式会社 アミジン誘導体及びそれを構成成分とする薬物担体
WO1998007409A1 (en) 1996-08-23 1998-02-26 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
SK283760B6 (sk) 1996-10-15 2004-01-08 The Liposome Company, Inc. Farmaceutický prostriedok na dopravu bioaktívnych látok
CA2276267C (en) * 1996-10-15 2009-12-22 The Liposome Company, Inc. Peptide-lipid conjugates, liposomes and liposomal drug delivery
WO1998027209A1 (en) 1996-12-18 1998-06-25 Emory University Polycationic oligomers
AU6178198A (en) 1997-03-07 1998-09-22 Sanofi Pharmaceuticals, Inc. Method of treating a tumor
JPH10253632A (ja) * 1997-03-10 1998-09-25 Nissui Pharm Co Ltd 分析方法、キット及び装置
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6524613B1 (en) * 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
US6272370B1 (en) * 1998-08-07 2001-08-07 The Regents Of University Of Minnesota MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging
AU7984498A (en) 1997-06-25 1999-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Serum-free cell growth medium
CA2297103A1 (en) * 1997-07-15 1999-01-28 The Regents Of The University Of California Isolated dna encoding human calcium activated potassium channel
ATE376062T1 (de) 1997-08-04 2007-11-15 Cell Genesys Inc Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
PT1019094E (pt) * 1997-10-02 2004-03-31 Epix Medical Inc Metodo de diagnostico por imagiologia com contraste intensificado para monitorizacao de terapias de intervencao
US6749863B1 (en) * 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
US6320017B1 (en) * 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
WO1999041403A1 (en) * 1998-02-12 1999-08-19 The Regents Of The University Of California Compositions for receptor/liposome mediated transfection and methods of using same
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6245427B1 (en) * 1998-07-06 2001-06-12 DüZGüNES NEJAT Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
DK1121117T3 (da) * 1998-10-14 2002-09-16 Debiopharm Sa Indpakning af et oxaliplatinholdigt præparat
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
JP2003502025A (ja) 1999-05-17 2003-01-21 エイブイアイ バイオファーマ, インコーポレイテッド hcGワクチンを用いた癌の処置のための併用アプローチ
JP2001002592A (ja) 1999-06-18 2001-01-09 Dai Ichi Seiyaku Co Ltd 遺伝子導入用組成物
US6280054B1 (en) * 1999-07-02 2001-08-28 Zight Corporation Image generator having an improved illumination system
US6242188B1 (en) * 1999-07-30 2001-06-05 Applied Gene Technologies, Inc. Sample processing to release nucleic acids for direct detection
WO2001011826A1 (fr) * 1999-08-09 2001-02-15 Fujitsu Limited Dispositif et technique de commande de paquets
CZ298581B6 (cs) 1999-08-30 2007-11-14 Debiopharm S. A. Farmaceuticky stabilní prípravek oxaliplatiny k parenterální aplikaci
AP2002002546A0 (en) 1999-12-30 2002-06-30 Judith K Gwathmey Iron chelator delivery system.
CN1433478A (zh) 1999-12-30 2003-07-30 诺瓦提斯公司 用于基因治疗的新的胶体合成载体
WO2001051003A2 (en) * 2000-01-10 2001-07-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US6530944B2 (en) * 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7001735B2 (en) * 2000-03-01 2006-02-21 Albert Einstein College Of Medicine Of Yeshiva University Glucose transporter/sensor protein and uses thereof
DE60130741T2 (de) * 2000-03-02 2008-07-03 Mitsubishi Pharma Corp. GPib-GEBUNDENES KONSTRUKT UND VERWENDUNGEN DAVON
JP4449147B2 (ja) 2000-03-22 2010-04-14 日油株式会社 ホスファチジルエタノールアミン誘導体の製造方法
FR2806727A1 (fr) 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
ATE336267T1 (de) 2000-04-12 2006-09-15 Liplasome Pharma As Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe
EP1278512A2 (en) * 2000-05-03 2003-01-29 MBT Munich Biotechnology AG Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US20030059461A1 (en) * 2000-06-06 2003-03-27 Sibtech, Inc. Molecular delivery vehicle for delivery of selected compounds to targets
US20030072794A1 (en) * 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
EP1370572B1 (en) * 2000-09-11 2008-11-26 Institut Pasteur Mitochondrial membrane permeabilization by hiv-1 vpr and methods of screening
US20040234588A1 (en) 2000-09-21 2004-11-25 University Of Georgia Research Foundation, Inc. Artificial lipoprotein carrier system for bioactive materials
EP1324758B1 (fr) 2000-10-03 2005-01-12 Debiopharm S.A. Microspheres de polymere de type plga/pla encapsulant des substances solubles dans l'eau, et leur procede de preparation
US20030129223A1 (en) * 2000-10-11 2003-07-10 Targesome, Inc. Targeted multivalent macromolecules
WO2002041870A2 (en) * 2000-11-22 2002-05-30 Vectron Therapeutics Ag Production and use of a targeted diagnostic system
EP1342063A4 (en) * 2000-12-12 2004-07-14 Australian Inst Marine Science ASSAY FOR PARLIAMENT CANCER POISON
AU2002223013A1 (en) 2000-12-12 2002-06-24 Debiopharm S.A. Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same
US6897196B1 (en) * 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
US6703524B2 (en) * 2001-02-20 2004-03-09 Lkt Laboratories, Inc. Organoselenium compounds for cancer chemoprevention
DK1368022T3 (da) 2001-03-02 2007-10-01 Debiopharm Sa Anvendelse af en flaske indeholdende en oxaliplatinoplösning
FI113840B (fi) 2001-03-26 2004-06-30 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa
US20040049022A1 (en) * 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
CA2445947A1 (en) 2001-04-30 2002-11-07 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
US20030082228A1 (en) * 2001-05-09 2003-05-01 Inex Pharmaceuticals Corporation Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
US20030108986A1 (en) * 2001-06-21 2003-06-12 Euroscreen, S.A. Compositions and methods comprising G-protein coupled receptors
WO2003004505A1 (en) 2001-07-02 2003-01-16 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
US20030096299A1 (en) * 2001-07-09 2003-05-22 Valerie Wittamer Natural ligand of G protein coupled receptor ChemR23 and uses thereof
US6793912B2 (en) * 2001-08-20 2004-09-21 Transave Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
DE10144252A1 (de) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
WO2003028640A2 (en) * 2001-10-03 2003-04-10 Vanderbilt University In vivo panning for ligands to radiation-induced molecules
AU2002346446A1 (en) 2001-11-20 2003-06-10 Baylor College Of Medicine Methods and compositions in checkpoint signaling
JP4468617B2 (ja) 2001-12-04 2010-05-26 デビオファーム エス.アー. 抗癌剤の併用投与方法及び併用可能な抗癌剤
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
EP1463759B8 (en) 2002-01-07 2013-07-10 Euroscreen S.A. Ligand for g-protein coupled receptor gpr43 and uses thereof
US20030220284A1 (en) 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
US7282567B2 (en) * 2002-06-14 2007-10-16 Immunomedics, Inc. Monoclonal antibody hPAM4
CA2513044A1 (en) * 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
AU2003215732B2 (en) * 2002-03-01 2009-12-17 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
WO2003082907A1 (en) 2002-03-29 2003-10-09 Euroscreen Sa Ligands for g protein coupled receptor gpr7 and uses thereof
CA2391438A1 (en) * 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
US20030228285A1 (en) 2002-05-03 2003-12-11 Mien-Chie Hung Bipartite T-cell factor (Tcf)-responsive promoter
US7460960B2 (en) 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
JP3415131B1 (ja) 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
FR2840236B1 (fr) 2002-06-03 2005-02-04 Inst Francais Du Petrole Membrane zeolithique de faible epaisseur, sa preparation et son utilisation en separation
CA2488753A1 (en) * 2002-06-07 2003-12-18 Immunomedics, Inc. Neutrophil imaging methods in cyctic fibrosis
US7238786B2 (en) * 2002-06-14 2007-07-03 Immunomedics, Inc. Monoclonal antibody cPAM4
US6790632B2 (en) 2002-06-17 2004-09-14 Stephen Eliot Zweig Membrane receptor reagent and assay
DE60334618D1 (de) * 2002-06-28 2010-12-02 Protiva Biotherapeutics Inc Verfahren und vorrichtung zur herstellung von liposomen
US7300655B2 (en) 2002-08-01 2007-11-27 Immunomedics, Inc. Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof
US20040132652A1 (en) * 2002-08-30 2004-07-08 Shire Biochem Inc. Pharmaceutical compositions
EP1572104A4 (en) 2002-11-14 2007-01-17 Kirk Sperber INDUCTION OF APOPTOSIS DURCHHIV-1-INFECTED MONOCYTE CELLS
US20060141019A1 (en) 2002-11-15 2006-06-29 Toshiya Kai Liposome
KR20050105454A (ko) 2003-02-17 2005-11-04 메비오팜 가부시키가이샤 암 치료약
AU2004232928A1 (en) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
CA2529027C (en) * 2003-06-13 2013-09-10 Immunomedics, Inc. D-amino acid peptides
US7109304B2 (en) * 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
JP2005154282A (ja) 2003-11-20 2005-06-16 Mebiopharm Co Ltd ガス封入リポソームの製造法
US7582430B2 (en) * 2004-01-20 2009-09-01 United States Of America As Represented By The Secretary Of The Army Immunoliposome-nucleic acid amplification (ILNAA) assay
US7212869B2 (en) * 2004-02-04 2007-05-01 Medtronic, Inc. Lead retention means
EP1579850A3 (en) 2004-03-15 2009-12-16 Nipro Corporation A pharmaceutical composition containing liposomes for treating a cancer
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2008030818A2 (en) 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions
JP5345792B2 (ja) 2008-02-19 2013-11-20 テイ・エス テック株式会社 車両用格納シート
JP5331648B2 (ja) 2009-10-22 2013-10-30 株式会社日立製作所 微粉炭ボイラの改造方法

Also Published As

Publication number Publication date
JP2008538105A (ja) 2008-10-09
US20110081404A1 (en) 2011-04-07
CN101170995B (zh) 2013-01-16
PT1863448E (pt) 2015-02-10
RU2007137492A (ru) 2009-04-20
NZ561569A (en) 2011-03-31
EP1863448B1 (en) 2014-11-26
AU2006223329A1 (en) 2006-09-21
ES2529453T3 (es) 2015-02-20
JP2006248978A (ja) 2006-09-21
US20140363491A1 (en) 2014-12-11
PL1863448T3 (pl) 2015-05-29
CN101170995A (zh) 2008-04-30
JP5438317B2 (ja) 2014-03-12
RU2454229C2 (ru) 2012-06-27
BRPI0608297A2 (pt) 2009-12-08
KR101352490B1 (ko) 2014-02-04
KR20080002819A (ko) 2008-01-04
HUE024290T2 (en) 2016-01-28
NO20075136L (no) 2007-12-07
CA2600446A1 (en) 2006-09-21
SI1863448T1 (sl) 2015-03-31
US8758810B2 (en) 2014-06-24
HK1111625A1 (en) 2008-08-15
US7829113B2 (en) 2010-11-09
DK1863448T3 (en) 2015-02-16
MX2007010996A (es) 2007-11-07
US20060222696A1 (en) 2006-10-05
WO2006099169A3 (en) 2007-02-22
CY1116075T1 (el) 2017-02-08
AU2006223329B2 (en) 2011-11-17
EP1863448A2 (en) 2007-12-12
WO2006099169A2 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
ZA200708600B (en) Novel liposome compositions
IL229521A0 (en) A new preparation
IL185901A0 (en) Novel composition
IL191572A0 (en) Pestcidal compositions
GB0503337D0 (en) Compositions
IL186721A0 (en) Bioenhanced compositions
EP1930012A4 (en) COMPOSITION CONTAINING A CELLO-OLIGOSACCHARIDE
GB0526283D0 (en) Compositions
EP1865042A4 (en) ANTI-FREEZE COMPOSITION
GB0501365D0 (en) Compositions
IL186093A0 (en) Lignan-containing compositions
GB0524128D0 (en) Compositions
EP1847249A4 (en) hair dye
GB0502479D0 (en) Novel compositions
GB0502475D0 (en) Novel compositions
ZA200709913B (en) Bioenhanced compositions
EP1947129A4 (en) PHOTORADIC AND PHOTOCYSTIC CURING COMPOSITION
EP1864573A4 (en) AGRICULTURAL CHEMICAL COMPOSITION
GB0525321D0 (en) Novel compositions
GB0505760D0 (en) Novel composition
GB0526282D0 (en) Compositions
GB0524803D0 (en) Novel compositions
GB0513367D0 (en) Novel composition
HK1101657A2 (en) Novel composition
GB0501364D0 (en) Compositions